Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2013-11-18 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release about the European Commission granting marketing authorization for a pharmaceutical product and related milestone payments. It does not contain financial statements or detailed financial data but rather an announcement of a corporate event. The document length is 3725 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-11-18 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a presentation made by the CEO at a healthcare conference, disclosing clinical trial results and program discontinuation. It is not a full financial report, audit, or earnings release. The document is relatively short (3367 characters) and serves as a regulatory announcement of material information rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-11-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an event (presentation of clinical study results at a conference) and references exhibits attached to the filing. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing reporting a material event, consistent with the purpose of Form 8-K filings. The document length is under 5,000 characters and it includes exhibits but does not contain the full reports themselves, only references to presentations. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2013-11-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a description of an event (presentation of a clinical study poster by GlaxoSmithKline at a conference) and references an exhibit (the poster). There are no financial statements or detailed financial data presented. The document is relatively short (4312 characters) and serves as an announcement of an event rather than a full financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-11-12 English
10-Q
Interim / Quarterly Report Q3 2013
2013-11-01 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release announcing the availability of a new prescription medicine (BREO ELLIPTA) in the U.S. It includes no financial statements or detailed financial data, nor does it contain management discussion or audit information. The document is short (3003 characters) and primarily serves as a notification of a corporate event (product availability announcement) rather than a financial report or detailed investor presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-10-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.